Globus Medical (GMED) Reports 25.2% Sales Growth in Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: NASDAQ.COM
- Strong Sales Performance: Globus Medical anticipates Q4 2025 sales of approximately $823.2 million, reflecting a 25.2% year-over-year increase, which underscores the robust growth in its spine business and solidifies its market position.
- Significant Annual Growth: For the full year 2025, the company expects sales to reach approximately $2.936 billion, representing a 16.5% increase from the previous year, indicating sustained expansion and rising demand in the medical device sector.
- Acquisition Impact: The completion of the $250 million acquisition of Nevro Corp. last year is expected to positively influence earnings in 2025, enhancing Globus's product portfolio and competitive edge in the market.
- Optimistic Outlook: The company has set revenue guidance for 2026 in the range of $3.18 billion to $3.22 billion, with projected fully diluted non-GAAP earnings per share between $4.30 and $4.40, reflecting management's confidence in future growth and clear strategic planning.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like GMED with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 101.00 USD with a low forecast of 87.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 91.830
Low
87.00
Averages
101.00
High
114.00
Current: 91.830
Low
87.00
Averages
101.00
High
114.00
About GMED
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bone Grafts Market Report: Forecast to 2036
- Market Size Forecast: The report indicates significant growth in the bone grafts and substitutes market projected by 2036, with detailed intervention volumes and market value data across 39 countries aiding strategic decision-making for businesses.
- Product Segmentation Analysis: It provides an in-depth analysis of various bone graft substitutes, including allograft bone chips and bone morphogenetic proteins, offering insights into market share and average selling prices to help companies optimize their product portfolios.
- Competitive Dynamics Insights: Through SWOT analysis and exploration of competitive dynamics, the report reveals the market positions of key players such as Medtronic and Stryker, assisting investors in identifying potential investment opportunities.
- Market Access Strategies: Additionally, the report offers detailed information on market access, including reimbursement policies and regulatory landscapes, enabling companies to formulate effective market entry strategies in a complex environment.
Continue Reading
Globus Medical CFO Kyle Kline Sells 3,594 Shares
- Executive Sell-off: On January 8, 2026, Globus Medical's CFO Kyle Kline sold 3,594 shares, which may raise concerns about the company's future performance, as executive sell-offs are often perceived as negative signals regarding company outlook.
- Market Reaction: While the specific sale price was not disclosed, executive stock transactions can significantly impact investor confidence, potentially leading to short-term stock price volatility, prompting investors to closely monitor subsequent market developments.
- Governance Concerns: Such executive sell-offs may trigger scrutiny of the company's governance structure, particularly regarding transparency and executive stock incentives, possibly prompting the company to enhance internal governance measures to maintain investor trust.
- Investor Strategy Adjustment: Investors may reassess their investment strategies in Globus Medical based on this news, especially in the current market environment, necessitating caution regarding the potential risks associated with executive sell-offs.
Continue Reading